Terminated PHASE3 INTERVENTIONAL 4-arm NCT04049175

Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma (PERSEA)

A 52 Week, Randomised, Double Blind, Multinational, Multicentre, 4-arm Parallel Group Trial to Assess the Efficacy and Safety of 3 Doses of CHF 6532 Compared to Placebo on Top of Standard of Care in Patients With Uncontrolled Severe Eosinophilic Asthma

Sponsor: Chiesi Farmaceutici S.p.A.

Conditions Asthma; Eosinophilic

Interventions Treatment A Treatment B Treatment C Treatment D

Updated 10 times since 2019 Last updated: Mar 30, 2022 Started: Aug 28, 2019 Primary completion: Oct 19, 2020 Completion: Feb 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

An interim analysis run by an independent data monitoring committee (DMC) to assess futility met the protocol-defined futility rules. The DMC recommended to stop the study for futility. The Sponsor issued a notification of early study termination.

Other terminated trials from Chiesi Farmaceutici S.p.A.

More terminations from Chiesi Farmaceutici S.p.A.

This PHASE3 trial investigates Asthma; Eosinophilic and is currently terminated or withdrawn. Chiesi Farmaceutici S.p.A. leads this study, which shows 10 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
May 2022 — Jul 2024 [monthly]

Terminated PHASE3
Dec 2021 — May 2022 [monthly]

Terminated PHASE3
Nov 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 5 earlier versions

Oct 2021 — Nov 2021 [monthly]

Terminated PHASE3

Status: Recruiting → Terminated
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE3
Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE3
Oct 2019 — Nov 2020 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Sep 2019 — Oct 2019 [monthly]

Not Yet Recruiting PHASE3

First recorded

Aug 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chiesi Farmaceutici S.p.A.

Data source: Chiesi Farmaceutici S.p.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stara Zagora, Bulgaria